Exploratory Study on POL6326 in Stem Cell Mobilization - Full Text View

Purpose

The purpose of this study is to determine whether POL6326 is safe and clinically active to mobilize hematopoietic stem cells followed by transplantation

Condition	Intervention	Phase
Multiple Myeloma	Drug: POL6326	Phase 2

Study Type:	Interventional
Study Design:	Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	A Phase IIa, Proof of Concept Study is to Determine the Degree of Mobilisation of CD34+ Cells Following Administration of POL6326 in Patients With Multiple Myeloma

Resource links provided by NLM:

MedlinePlus related topics: Multiple Myeloma

U.S. FDA Resources

Further study details as provided by Polyphor Ltd.:

Primary Outcome Measures:

To assess the ability of POL6326 to mobilise CD34+ hematopoietic stem cells in patients with primary multiple myeloma [ Time Frame: Up to four days ] [ Designated as safety issue: No ]
Number of patients achieving the minimal number of CD34+ cells (≥2 x 10 mill/kg BW) collected during one to four cycles of apheresis which are considered necessary and safe to proceed with autotransplantation

Number of apheresis cycles required to obtain the minimal number of CD34+ cells necessary for autotransplantation (≥2 x 10 mill/kg BW)

Secondary Outcome Measures:

To evaluate the safety and pharmacokinetics of POL6326 in patients with multiple myeloma [ Time Frame: 2 months ] [ Designated as safety issue: Yes ]
To determine the efficacy of POL6326 in reconstitution of immune system after transplantation [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Estimated Enrollment:	36
Study Start Date:	April 2009
Estimated Study Completion Date:	December 2013
Estimated Primary Completion Date:	December 2013 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: CD34+ mobilisation for transplantation	Drug: POL6326 IV infusion of POL6326 followed by apheresis to collect mobilized stem cells from peripheral blood Other Name: not appicable

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Have multiple myeloma in Stage II or III, according to the criteria of Durie and Salmon.
Male or female between 18 and 70 years of age, inclusive. Male and females capable of reproduction must agree to use adequate contraceptive measures (e.g. condom, intrauterine device, oral contraceptive) until 3 months after termination of treatment.
Measurable disease, defined by one of the following:
- Serum M protein ≥1.0 g/dL by protein electrophoresis
- Quantifiable immunoglobulin levels and/or
- urinary M protein excretion ≥200 mg/24 hours.
All patients have undergone 3 cycles of chemotherapy, with the last dose of chemotherapy given 3 to 8 weeks before study entry.
Eastern Cooperative Oncology Group (ECOG) performance status of 2.
Life expectancy of >6 months.
Have given their written informed consent to participate in the study

Exclusion Criteria:

Have non-secretory myeloma and/or plasma cell leukaemia.
History of other malignancies during the past 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin, cervical carcinoma, or localised prostate carcinoma.
Any other clinically significant medical conditions.
History of cardiac disease NHYA classification ≥3.
Insufficient bone marrow, liver and renal function as assessed by the following clinical laboratory evaluations:

Haemoglobin <9.0 g/L. Absolute neutrophil count <1500/µL. Platelet count <50000/µL. Total bilirubin >1.5 x upper limit of normal (ULN). Alanine aminotransferase (ALT) and alkaline phosphatase (AP) >2.5 x ULN. Amylase and lipase >1.5 x ULN. Serum creatinine >2.0 x ULN. Prothrombin time (PT) and activated partial thrombo-plastin time (aPTT) >1.5 x ULN.
Pregnant or lactating female patients.
Known history of HIV infection or chronic hepatitis B or C infection.
Receipt of immunotherapy, radiation therapy, or any investigational drug within 30 days of study drug administration.
Prior radiotherapy to more than 3 vertebrae.
Active serious bacterial or fungal infections; >grade 3 National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE).
Receipt of haematopoietic cytokines within 10 days of study drug administration.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01105403

Contacts

Contact: Hartmut Goldschmidt, MD

+49 6221-568003

Hartmut.Goldschmidt@med.uni-heidelberg.de

Locations

Germany
Department of Internal Medicine V	Recruiting
Heidelberg, Germany, 69115
Contact: Hartmut Goldschmidt, MD
Principal Investigator: Hartmut Goldschmidt, MD

Sponsors and Collaborators

Polyphor Ltd.

Investigators

Principal Investigator:

Hartmut Goldschmidt, MD

University of Heidelberg

More Information

No publications provided

Responsible Party:	Polyphor Ltd.
ClinicalTrials.gov Identifier:	NCT01105403 History of Changes
Other Study ID Numbers:	POL-2
Study First Received:	April 13, 2010
Last Updated:	March 30, 2013
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Polyphor Ltd.:

Hematopoietic stem cells
Mobilisation
Autologous transplantation

Additional relevant MeSH terms:

Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases

Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases

ClinicalTrials.gov processed this record on May 19, 2013